TABLE 3.
Characteristics of Patients With Deep Vein Thrombosis
| Patient | Age, y | Sex | Event | Regimen | Time of event | Prophylaxis at time of DVT | Steroid dose at time of DVT | Lenalidomide dose at time of DVT | Contributing factors |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 65 | M | PE | RD | 4th cycle | None | 40 mg Days 1–4, 9–12, 17–20 every 28 d | 25 mg Days 1–21, every 28 d | None |
| 2 | 67 | M | DVT | RD | 3rd cycle | Aspirin 325 mg/d | 40 mg Days 1–4, 9–12, 17–20 every 28 d | 25 mg Days 1–21, every 28 d | None |
| 3 | 79 | M | DVT | RLD | 6th cycle | Aspirin 325 mg/d | 40 mg Days 1, 8, 15, 22 every 28 d | 15 mg Days 1–21, every 28 d | None |
| 4 | 67 | M | DVT | RD | 5th cycle | Aspirin 325 mg/d | 40 mg Days 1–4, 9–12, 17–20 every 28 d | 25 mg Days 1–21, every 28 d | None |
| 5 | 72 | M | DVT | RD | 4th cycle | Aspirin 325 mg/d | 40 mg Days 1–4, 9–12, 17–20 every 28 d | 15 mg Days 1–21, every 28 d | None |
| 6 | 71 | W | PE | RD | 4th cycle | None | 40 mg Days 1–3, 9–11, 17–19 every 28 d; plus tapering doses on Days 4, 5, 12, 13, 20, 21 | Not available | None |
| 7 | 64 | M | PE | RD | 16th cycle | Aspirin 325 mg/d | None | 25 mg Days 1–21, every 28 d | On coumadin at baseline for PE diagnosed during w/u of myeloma. Developed PE within a mo of switching to ASA from coumadin |
| 8 | 71 | W | DVT | MPR | 7th cycle | None | Pred 2 mg/kg Days 1–4 every 28 d | 10 mg Days 1–21, every 28 d | Stopped ASA 3 mo before for thrombocytopenia |
| 9 | 72 | W | PE | MPR | 1st cycle | Aspirin 100 mg/d | Pred 2 mg/kg Days 1–4 every 28 d | 10 mg Days 1–21, every 28 d | None |
| 10 | 68 | M | DVT | MPR | 6th mo of maintenance phase | None | None | 10 mg Days 1–21, every 28 d | ASA discontinued for thrombocytopenia |
M indicates men; W, women; RD, lenalidomide plus high dose dexamethasone; RLD, Lenalidomide plus low dose dexamethasone; MPR, melphalan, prednisone, lenalidomide; DVT, deep vein thrombosis; PE, pulmonary embolism.